Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07377929 · ClinicalTrials.gov registry record
Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms
A clinical trial of Lower Urinary Track Symptoms and Benign Prostatic Hypertrophy (BPH), sponsored by Benaroya Research Institute.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT07377929: Recruiting study of Lower Urinary Track Symptoms and Benign Prostatic Hypertrophy (BPH), sponsored by Benaroya Research Institute.
NCT07377929 is a study of Lower Urinary Track Symptoms and Benign Prostatic Hypertrophy (BPH) that is actively recruiting participants, run by Benaroya Research Institute. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07377929, a study of Lower Urinary Track Symptoms and Benign Prostatic Hypertrophy (BPH), is actively recruiting participants, sponsored by Benaroya Research Institute.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with longstanding obstructive lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH) can also develop symptoms of overactive bladder syndrome (OAB). Transurethral resection of the prostate (TURP) and Transurethral Waterjet Ablation of the Prostate (Aquablation) are amongst the gold standard surgical treatments for BPH. However, in the immediate post-operative period, TURP and Aquablation can also include OAB-like symptoms, including urinary frequency and urgency. For men with baseline OAB symptoms, this initial worsening of symptoms can be distressing. Botox is an FDA approved medication with on-label indications to treat overactive bladder. The purpose of this study is to evaluate the outcomes of men who have Botox concurrent with their TURP or Aquablation.
Primary Outcome
This will be measured using Postoperative Urinary Retention (POUR): At 1 week post-operative visit for trial of void to assess for rates of postoperative urinary retention. At 4 and 12 week post-operative visits for post void residual assessment
Conditions Studied
Interventions
- OTHER Survey using a questionnaire.
Study Locations (1)
Washington
- Virginia Mason Franciscan Health - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-19 |
| Est. Completion | 2027-05-01 |
What NCT07377929 shows while recruiting
NCT07377929 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 2 conditions, with Lower Urinary Track Symptoms appearing as the primary indexed condition, and to 1 intervention - of which Survey using a questionnaire. is the first listed.
NCT07377929 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT07377929 about?
NCT07377929 is a clinical study titled "Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms". Patients with longstanding obstructive lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH) can also develop symptoms of overactive bladder syndrome (OAB). Transurethral resection of the prostate (TURP) and Transurethral Waterjet Ablation of the Prostate (Aquablation) are am...
What is the current status of trial NCT07377929?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2026-01-19. Estimated completion is 2027-05-01.
What conditions does trial NCT07377929 study?
This clinical trial studies the following conditions: Lower Urinary Track Symptoms, Benign Prostatic Hypertrophy (BPH).
What interventions are being tested in trial NCT07377929?
The interventions under investigation include: Survey using a questionnaire. (OTHER).
Who is sponsoring clinical trial NCT07377929?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07377929 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lower Urinary Track Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI